Zobrazeno 1 - 10
of 210
pro vyhledávání: '"Peter B. Luppa"'
Autor:
Peter B. Luppa, Michael Zeller, Marija Pieper, Patricia Kaiser, Nathalie Weiss, Laura Vierbaum, Guido Freckmann
Publikováno v:
Frontiers in Molecular Biosciences, Vol 11 (2024)
Background:During the last decade, Germany has seen an increased prevalence and a redistribution from undetected to diagnosed diabetes mellitus. Due to this substantial epidemiological development, the number of people with documented type 2 diabetes
Externí odkaz:
https://doaj.org/article/c91e3e039fd24d718efdaf2173014252
Autor:
Laura Vierbaum, Nathalie Weiss, Patricia Kaiser, Marcel Kremser, Folker Wenzel, Mario Thevis, Ingo Schellenberg, Peter B. Luppa
Publikováno v:
Frontiers in Molecular Biosciences, Vol 11 (2024)
As hormonal disorders are linked to several diseases, the accurate quantitation of steroid hormone levels in serum is crucial in order to provide patients with a reliable diagnosis. Mass spectrometry-based methods are regarded as having the highest l
Externí odkaz:
https://doaj.org/article/c52fdfe1616d4a3c8c6a8428f510b6bd
Autor:
Isabel Wustrow, Christopher Ebner, Nicolas Langwieser, Bernhard Haller, Peter B. Luppa, Christian Bradaric, Dario Bongiovanni, Anja Stundl, Karl-Ludwig Laugwitz, Tareq Ibrahim, Isabell Bernlochner
Publikováno v:
Platelets, Vol 32, Iss 3, Pp 398-403 (2021)
The extent of the involvement of platelets in venous thromboembolisms (VTE) is still not fully understood. Immature platelets are large, RNA-rich, prothrombotic platelets. They are involved in arterial thromboembolisms and are associated with adverse
Externí odkaz:
https://doaj.org/article/f0141897cee44487a68986d99cf86e37
Autor:
Melina K. Grasmeier, Anna F. Langmann, Peter Langmann, Matthias Treiber, Markus A. Thaler, Peter B. Luppa
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Antibodies to infliximab (ATI) in serum are associated with secondary loss of response (LOR) to infliximab (IFX) therapy in patients with inflammatory bowel disease (IBD). However, feasible ATI-related predictors of therapy success are la
Externí odkaz:
https://doaj.org/article/2a752b3c17864cdf8a98722fd95e6822
Autor:
Andreas Umgelter, Katrin S. Wagner, Wolfgang Reindl, Peter B. Luppa, Fabian Geisler, Wolfgang Huber, Roland M. Schmid
Publikováno v:
Annals of Hepatology, Vol 11, Iss 2, Pp 232-239 (2012)
Introduction. Hepatorenal syndrome type I (HRS I) may be a consequence of circulatory dysfunction in cirrhotic patients with portal hypertension. This uncontrolled interventional pilot study examines the hemodynamic and renal effects of large volume
Externí odkaz:
https://doaj.org/article/c0af5a5c586442baa6e826bc05c0f4ea
Autor:
Ralf Junker, Peter B. Luppa
Publikováno v:
Journal of Laboratory Medicine. 47:87-95
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 61:1255-1265
Objectives The therapeutic antibody infliximab (IFX) has improved the life quality of numerous autoinflammatory disease patients. However, IFX can trigger the generation of anti-drug antibodies (ADA), whose optimal evaluation and management are curre
Autor:
Daniel Stern, Jasmin Weisemann, Alexander Le Blanc, Laura von Berg, Stefan Mahrhold, Janett Piesker, Michael Laue, Peter B Luppa, Martin Bernhard Dorner, Brigitte Gertrud Dorner, Andreas Rummel
Publikováno v:
PLoS Pathogens, Vol 14, Iss 5, p e1007048 (2018)
The exceptional toxicity of botulinum neurotoxins (BoNTs) is mediated by high avidity binding to complex polysialogangliosides and intraluminal segments of synaptic vesicle proteins embedded in the presynaptic membrane. One peculiarity is an exposed
Externí odkaz:
https://doaj.org/article/e2d7b5069a704ba685309c608ccd0a45
Publikováno v:
Analytical and Bioanalytical Chemistry. 414:3161-3163
Autor:
Chen Liu, Susanne Weber, Rong Peng, Long Wu, Wen-shu Zhang, Peter B. Luppa, Jürgen Popp, Dana Cialla-May
Publikováno v:
TrAC Trends in Analytical Chemistry. 164:117094